AzurRx reports Phase IIa data for MS1819 in chronic pancreatitis

In September, AzurRx BioPharma Inc. (NASDAQ:AZRX) reported data from 6 patients with chronic pancreatitis in a Phase IIa trial showing that once-daily MS1819 for 48-60

Read the full 255 word article

User Sign In